Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: KínaFázis nélkül

A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries

A legfontosabb adatok

Ki végzi
FrontAce Scientific Co., Ltd
Hol
Beijing, Chengdu, Chongqing, Hangzhou, Luzhou, Nanjing, Nantong, Shanghai, Shijiazhuang, Wuhan és Zhengzhou (Kína)Mind a 12 helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
240 fő, tervezett
Kezdés
2024. jún. 4.
Várható befejezés
2026. dec. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Sperstent® peripheral spot stent system
  • Everflex® self-expanding peripheral stent system
A regiszteradat frissítve
2024. augusztus 6.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with narrowed or blocked leg arteries in the thigh or behind the knee. They must still have narrowing or a tear in the artery wall after balloon treatment. The trial compares two stents (small metal tubes that hold the artery open).

Életkor
18 to 85 years
Nem
All sexes
A betegség stádiuma
Peripheral artery disease with symptoms of Rutherford class 2 to 5, in the superficial femoral artery or the upper popliteal artery. Narrowing of at least 70%, or a full blockage shorter than 150mm. Total lesion length 50mm to 250mm, vessel size 3 mm to 7.5 mm. Expected to live more than 1 year.
Korábbi kezelés
After balloon treatment with a DCB, more than 30% narrowing or at least one tear in the artery wall must remain. People cannot join if they had bypass or other open surgery on the artery, or a stent already in it.

A részvétel fő kizáró okai

  • Serum creatinine >2.5mg/dl (221 µmol/L), or long-term haemodialysis or peritoneal dialysis
  • Heart attack or stroke with symptoms within 3 months
  • Severe bleeding or clotting disorder, or a past or planned organ transplant
  • Allergy to contrast agents, nickel or titanium, heparin, aspirin, clopidogrel or anaesthetics
  • Pregnancy, breastfeeding, or plans for a family within 1 year

A regiszter feltételei, szó szerint

Mind a 30 feltétel megnézéseKevesebb

Ki vehet részt

  • Age 18-85 years old, male or female
  • The target lesion is located in the superficial femoral artery or the proximal popliteal artery
  • Peripheral arterial stenosis or occlusive disease with symptoms consistent with the Rutherford classification 2 to 5
  • Estimated life expectancy >1 year
  • Subject has been informed of and understands the nature of the study and provides signed informed consent to participate in the study; Angiographic Inclusion Criteria:
  • Stenosis rate ≥70% under DSA by visual estimate, or 100% occluded lesion with a total lesion length less than 150mm (by visual estimate)
  • Reference vessel diameter is between 3 mm and 7.5 mm, 50mm≤Total cumulative length of target lesions≤250mm; (In the case of bilimb lesions, a single target lesion with one limb meeting the protocol criteria is selected by the investigator; More than 2cm between lesions are considered as 2 lesions)
  • After PTA treatment by DCB, there exists residual lesions, such as the target lesion has over 30% residual DS and/or presence of at least one post-PTA dissection (Type A-F) (by visual estimate)
  • Patients with unobstructed inflow tract or successfully treated, visual residual stenosis ≤50%
  • Angiography showed at least one outflow tract was unobstructed at the distal end (Stenosis degree ≤70% before intervention)

Ki nem vehet részt

  • Target vessel had undergone open surgery such as bypass surgery or the target lesion is in-stent restenosis
  • A history of major organ failure or other serious illness (including severe coronary heart disease, severe cardiac insufficiency, severe neurosis, or mental illness); Have received or plan organ transplantation, severe gastrointestinal bleeding)
  • Myocardial infarction or symptomatic stroke occurred within 3 months prior to enrollment
  • Thrombolysis of target vessel within 72 hours before surgery, did not completely dissolve the thrombus
  • Endovascular or surgical procedures are performed on the target limb within 30 days before or 30 days after surgery
  • Participating in clinical trials of other medical devices or drugs
  • During the procedure, the target lesions had received or were scheduled to receive volume reduction procedures such as cryogenic angioplasty, laser angioplasty, and percutaneous intracavity plaque gyrotomy;
  • Severe coagulation disorder
  • Patients with major vascular-related diseases, including acute lower extremity ischemia, active disseminated intravascular coagulation, thromboangiitis obliterans, deep vein thrombosis, and aneurysms of therapeutic lateral vessels (deep femur, superficial femur, or popliteal artery)
  • Systemic infection or uncontrolled infection within the target limb
  • Known allergy to contrast agents, nickel or titanium (Nitinol), heparin, aspirin, clopidogrel, anesthetics
  • Failure of the guidewire to pass through the lesion;
  • Acute vascular occlusion or acute or subacute thrombosis in the target lesion;
  • Patients with serum creatinine >2.5mg/dl during screening or undergoing long-term hemodialysis or peritoneal dialysis
  • Women who are pregnant or breast-feeding, or women of childbearing age who have family plans within 1 year
  • Patients who are planning to have major lower limb amputations on the target side of the lesion
  • The investigator considers the patient is not suitable for participation in the clinical trial; Angiographic Exclusion Criteria:
  • The target lesion before stent implantation is thrombotic obliteration, which is not suitable for stent implantation;
  • The target lesions were severely calcified and could not fully predilate; Or grade 4 calcification;
  • Stent was implanted into the target vessel before enrollment

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 85 év között vagy?

Helyszínek itt: Kína

  • Beijing Friendship Hospital, Capital Medical UniversityBeijing, KínaContact: Hai FengToborzás még nem indult
  • Hospital of Chengdu University of TCMChengdu, KínaContact: Chunshui HeToborzás még nem indult
  • The First Affiliated Hospital of Chongqing Medical UniversityChongqing, KínaContact: Yu ZhaoToborzás még nem indult
  • The First Affiliated Hospital Zhejiang University School of MedicineHangzhou, KínaContact: Hongkun ZhangToborzás még nem indult
  • The Affiliated Hospital of Southwest Medical UniversityLuzhou, KínaContact: Yong LiuToborzás még nem indult
  • Nanjing Drum Tower hospitalNanjing, KínaContact: Min ZhouRésztvevőt keres
  • Affiliated Hospital of Nantong UniversityNantong, KínaContact: Hui ZhaoToborzás még nem indult
  • Renji Hospital Shanghai Jiao Tong University School of MedicineShanghai, KínaContact: Meng YeToborzás még nem indult
  • Shanghai East HospitalShanghai, KínaContact: Xiang WangRésztvevőt keres
  • The Second Hospital of Hebei Medical UniversityShijiazhuang, KínaContact: Wei BiToborzás még nem indult
  • Liyuan Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, KínaContact: Zibo FengRésztvevőt keres
  • First Affiliated Hospital of Zhengzhou UniversityZhengzhou, KínaContact: Zhen LiToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a prospective, multi-center, randomized trial designed to investigate the efficacy and safety of Sperstent® peripheral spot stent system versus Everflex® self-expanding peripheral stent system in the endovascular treatment of post-balloon angioplasty (post-PTA) residual lesions including stenoses and/or dissections in femoral and proximal popliteal arteries.

A vizsgálat 2 csoportja

  • Sperstent® peripheral spot stent systemA vizsgált kezelés

    subjects using the Sperstent® peripheral spot stent system

  • Everflex® self-expanding peripheral stent systemMár használt kezelés, összehasonlításként

    subjects using the Everflex® self-expanding peripheral stent system

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Prospective, Multicenter and Randomized Controlled Trial to Evaluate the Efficacy and Safety of Sperstent® Peripheral Spot Stent System Used for the Residual Lesions After Percutaneous Transluminal Angioplasty of Femoropopliteal Arteries
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT06539689: ki vehet részt
A regiszteradat frissítve
2024. augusztus 6.